Bristol Myers Squibb (NYSE: BMY) shareholders are certainly finishing the trading week on a high note. The drugmaker’s stock is up 9.6% as of 1:14 p.m. ET, according to data from S&P Global Market Intelligence, in response to a surprisingly strong second-quarter report and subsequently raised full-year guidance.
Give credit to Bristol Myers Squibb’s newer drugs like Opdivo, Yervoy, and Opdualag. These cancer-fighting treatments led the company’s so-called Growth Portfolio to total revenue of $5.6 billion, up 18% year over year. Meanwhile, its legacy portfolio — largely made up of blood-thinning Eliquis and oncology drug Revlimid — still managed to produce modest growth. All told, Q2’s top line grew 9% year over year to $12.2 billion, beating estimates of only $11.5 billion. Per-share profits of $2.07 were up from the year-ago comparison of $1.75, also topping estimates of $1.63 per share.
This pace of forward progress isn’t apt to slow in the foreseeable future, either. Bristol Myers Squibb upped its full-year revenue forecast slightly, in addition to raising its 2024 earnings guidance from a range of only $0.40-$0.70 per share to a new prediction of $0.60-$0.90 per share.
The pharmaceutical giant’s bottom line is likely to be lifted by the U.S. launch of schizophrenia and neurodegenerative disease therapy KarXT later this year.
A big jump like this one is a tough act to follow, which is why many people simply don’t buy stocks after such moves.
Bristol Myers Squibb, however, may be a worthy exception to this line of thinking. Even with Friday’s sizable rally, shares are still 40% below their November 2022 high, nearer the multiyear low reached earlier this month.
What’s the deal? Investors were largely fearing the worst for Eliquis and Revlimid before sales of the company’s newer drugs reached their full stride. Now we can see these worries may have been overblown. The stock’s still undervalued compared to the company’s potential though. It’s also an attractive dividend prospect, with its recent weakness pumping up the forward-looking dividend yield up to 5.3%.
That’s based on a dividend, by the way, that’s been raised every year for the past 15 years.
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $688,005!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of July 22, 2024
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
